Two COVID-19 vaccines against Omicron BA.4/5 approved in US
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- New Ocrevus Subcutaneous Injection Therapy Shows Promising Results in Multiple Sclerosis Treatmen
- Dutch Man Infected with COVID-19 for 613 Days Dies: Accumulating Over 50 Virus Mutations
Two COVID-19 vaccines against Omicron BA.4/5 approved in US
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Two COVID-19 vaccines against Omicron BA.4/5 approved in US.
On August 31, the bivalent (against two strains) COVID-19 vaccines developed by Moderna and Pfizer-BioNTech were approved for emergency use in the United States, respectively for booster vaccination of people aged 18 and over and 12 years and over.
These two vaccines are designed based on the original strain and the currently circulating Omicron BA.4/5.
Peter Marks, head of the U.S. Food and Drug Administration’s (FDA) vaccine division, said at a news conference on the same day that this year’s fall and winter epidemic wave is expected to peak in early December, and the updated booster vaccine has Help control current infection rates and prevent future surges.
According to data from the US Centers for Disease Control and Prevention , Omicron BA.5 has replaced BA.2 as the main epidemic strain since June. Last week, Omicron BA.5 accounted for 88.7%, BA.4 and Its branches accounted for 11.1%.
The two newly approved vaccines can further reduce the severe disease and mortality caused by Omicron, but in terms of dealing with the breakthrough infection rate of future mutants , the effect is more limited.
It is worth noting that both vaccines currently lack human-related clinical trial data. The FDA’s approval is mainly based on the mouse experimental data of the two vaccines and the human test results of Moderna’s other bivalent vaccine (including the original strain and Omicron BA.1).
The FDA said it hopes the updated vaccine will boost antibody levels to return to the high protection rates of the original vaccine, but it is not yet certain when clinical data for both vaccines will be available.
Experts believe that the new generation of vaccines developed by the mRNA technology route only needs to change part of the sequence to improve its effectiveness, and the safety will not change, which is also an advantage that other technology routes do not have.
Two weeks ago, the bivalent COVID-19 vaccine developed by Moderna against the original strain and Omicron BA.1 was the first to be approved in the UK for adult booster immunization.
Two COVID-19 vaccines against Omicron BA.4/5 approved in US
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
